AVEO: Data Provides Rationale For Investigation Of AV-203 As Anticancer Therapy

(RTTNews) - AVEO Oncology (AVEO) announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO's ErbB3 (HER3) inhibitory antibody candidate. The company said the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy.

The recommended Phase 2 dose was established at 20mg/kg intravenously every 2 weeks. No anti-drug antibodies were detected, and pharmacokinetic results indicated a dose-proportional increase in levels of AV-203.